Details:
The contract will support development of a prophylactic vaccine against enterovirus D68 (EV D68). Intravacc will develop an inactivated EV D68 vaccine, based on Intravacc's proprietary Vero cell technology, from early product selection through to Phase I clinical testing.
Lead Product(s): Inactivated EV D68 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $9.4 million Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2020
Details:
The aim of this partnership is to develop an intranasal vaccine to protect humans against COVID-19. The vaccine will consist of a Newcastle disease virus vector that expresses the immunogenic spike protein of SARS-CoV-2.
Lead Product(s): COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Wageningen Bioveterinary Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 04, 2020
Details:
Intravacc is focusing on emergency and conventional vaccines. Intravacc’s emergency vaccine is designed to activate T-cell responses. This emergency vaccine would aid in reduction of mortality and morbidity, thus aims to reduce the pressure on the public health system.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Following treatment with RUCONEST®, fever resolved in four of the five patients within 48 hours, and laboratory markers of inflammation decreased significantly (CRP, IL-6).
Lead Product(s): Conestat alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020